Literature DB >> 16489751

Solution structure of an oncogenic mutant of Cdc42Hs.

Paul D Adams1, Robert E Oswald.   

Abstract

Cdc42Hs(F28L) is a single-point mutant of Cdc42Hs, a member of the Ras superfamily of GTP-binding proteins, that facilitates cellular transformation brought about by an increased rate of cycling between GTP and GDP [Lin, R., et al. (1997) Curr. Biol. 7, 794-797]. Dynamics studies of Cdc42Hs(F28L)-GDP have shown increased flexibility for several residues at the nucleotide-binding site [Adams, P. D., et al. (2004) Biochemistry 43, 9968-9977]. The solution structure of Cdc42Hs-GDP (wild type) has previously been determined by NMR spectroscopy [Feltham, J. L., et al. (1997) Biochemistry 36, 8755-8766]. Here, we describe the solution structure of Cdc42Hs(F28L)-GDP, which provides insight into the structural basis for the change in affinity for GDP. Heteronuclear NMR experiments were performed to assign resonances in the protein, and distance, hydrogen bonding, residual dipolar coupling, and dihedral angle constraints were used to calculate a set of low-energy structures using distance geometry and simulated annealing refinement protocols. The overall structure of Cdc42Hs(F28L)-GDP is very similar to that of wild-type Cdc42Hs, consisting of a centrally located six-stranded beta-sheet structure surrounding the C-terminal alpha-helix [Feltham, J. L., et al. (1997) Biochemistry 36, 8755-8766]. In addition, the same three regions in wild-type Cdc42Hs that show structural disorder (Switch I, Switch II, and the Insert region) are disordered in F28L as well. Although the structure of Cdc42Hs(F28L)-GDP is very similar to that of the wild type, interactions with the nucleotide and hydrogen bonding within the nucleotide binding site are altered, and the region surrounding L28 is substantially more disordered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16489751      PMCID: PMC2566826          DOI: 10.1021/bi051686g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  33 in total

1.  The Xplor-NIH NMR molecular structure determination package.

Authors:  Charles D Schwieters; John J Kuszewski; Nico Tjandra; G Marius Clore
Journal:  J Magn Reson       Date:  2003-01       Impact factor: 2.229

2.  The crystal structure of human rac1, a member of the rho-family complexed with a GTP analogue.

Authors:  M Hirshberg; R W Stockley; G Dodson; M R Webb
Journal:  Nat Struct Biol       Date:  1997-02

3.  The program XEASY for computer-supported NMR spectral analysis of biological macromolecules.

Authors:  C Bartels; T H Xia; M Billeter; P Güntert; K Wüthrich
Journal:  J Biomol NMR       Date:  1995-07       Impact factor: 2.835

4.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

5.  Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia.

Authors:  J L Bos; D Toksoz; C J Marshall; M Verlaan-de Vries; G H Veeneman; A J van der Eb; J H van Boom; J W Janssen; A C Steenvoorden
Journal:  Nature       Date:  1985 Jun 27-Jul 3       Impact factor: 49.962

6.  A novel Cdc42Hs mutant induces cellular transformation.

Authors:  R Lin; S Bagrodia; R Cerione; D Manor
Journal:  Curr Biol       Date:  1997-10-01       Impact factor: 10.834

7.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

Authors:  C J Farr; R K Saiki; H A Erlich; F McCormick; C J Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Backbone dynamics of an oncogenic mutant of Cdc42Hs shows increased flexibility at the nucleotide-binding site.

Authors:  Paul D Adams; Adrienne P Loh; Robert E Oswald
Journal:  Biochemistry       Date:  2004-08-10       Impact factor: 3.162

9.  The identification and characterization of a GDP-dissociation inhibitor (GDI) for the CDC42Hs protein.

Authors:  D Leonard; M J Hart; J V Platko; A Eva; W Henzel; T Evans; R A Cerione
Journal:  J Biol Chem       Date:  1992-11-15       Impact factor: 5.157

10.  Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis.

Authors:  E F Pai; U Krengel; G A Petsko; R S Goody; W Kabsch; A Wittinghofer
Journal:  EMBO J       Date:  1990-08       Impact factor: 11.598

View more
  6 in total

1.  Unique structural and nucleotide exchange features of the Rho1 GTPase of Entamoeba histolytica.

Authors:  Dustin E Bosch; Erika S Wittchen; Connie Qiu; Keith Burridge; David P Siderovski
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

2.  Detection of Ras GTPase protein radicals through immuno-spin trapping.

Authors:  Michael F Davis; Li Zhou; Marilyn Ehrenshaft; Kalina Ranguelova; Harsha P Gunawardena; Xian Chen; Marcelo G Bonini; Ronald P Mason; Sharon L Campbell
Journal:  Free Radic Biol Med       Date:  2012-07-20       Impact factor: 7.376

3.  A switch I mutant of Cdc42 exhibits less conformational freedom.

Authors:  Reena Chandrashekar; Omar Salem; Hana Krizova; Robert McFeeters; Paul D Adams
Journal:  Biochemistry       Date:  2011-06-24       Impact factor: 3.162

4.  Alchemical Free Energy Calculations to Investigate Protein-Protein Interactions: the Case of the CDC42/PAK1 Complex.

Authors:  Maria Antonietta La Serra; Pietro Vidossich; Isabella Acquistapace; Anand K Ganesan; Marco De Vivo
Journal:  J Chem Inf Model       Date:  2022-06-09       Impact factor: 6.162

5.  RAC1P29S is a spontaneously activating cancer-associated GTPase.

Authors:  Matthew J Davis; Byung Hak Ha; Edna C Holman; Ruth Halaban; Joseph Schlessinger; Titus J Boggon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-02       Impact factor: 11.205

6.  Optimization and stabilization of Rho small GTPase proteins for solution NMR studies: The case of Rnd1.

Authors:  Shufen Cao; Matthias Buck
Journal:  Small GTPases       Date:  2011-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.